SHANGHAI – Genhui Chen, CEO and co-founder of Beijing Wenfeng Tianji Pharma Ltd., is at the end of a long road. He is an inventor-entrepreneur waiting patiently for the CFDA to give him the good news he is hoping for: that benvitimod, the first-in-class small-molecule drug he has been developing since the late 1990s, will be approved for mild to moderate psoriasis in China.
SHANGHAI – Genhui Chen, CEO and co-founder of Beijing Wenfeng Tianji Pharma Ltd., is at the end of a long road. He is an inventor-entrepreneur waiting patiently for the CFDA to give him the good news he is hoping for: that benvitimod, the first-in-class small-molecule drug he has been developing since the late 1990s, will be approved for mild to moderate psoriasis in China.
SHANGHAI – At China Trials 10, the optimism around the recent regulatory reforms – specifically those opening China to early stage and multiregional clinical trials – come with a hint of anxiety, as evidenced in the conference title: "Entering the New Era of China Clinical Development – Are We Ready?"
SHANGHAI – Suzhou-based Cstone Pharmaceuticals Co. Ltd. is now a clinical-stage company with the dosing of its first Chinese patient with CS-1001, an anti-PD-L1 monoclonal antibody. In a full field of PD-1 antibodies, Cstone is betting CS-1001 will differentiate it as the first of its kind for China, a fully human and full length programmed cell death protein ligand 1 (PD-L1). The company has gone from zero to entering the clinic at a blistering pace. It was just over a year ago when Cstone made a splash, raising an eye-catching $150 million in series A financing – a record for China. The firm also attracted well-known pharma executives such as Frank Jiang, former Asia Pacific R&D head for Sanofi SA.
SHANGHAI – Suzhou-based Cstone Pharmaceuticals Co. Ltd. is now a clinical-stage company with the dosing of its first Chinese patient with CS-1001, an anti-PD-L1 monoclonal antibody. In a full field of PD-1 antibodies, Cstone is betting CS-1001 will differentiate it as the first of its kind for China, a fully human and full length programmed cell death protein ligand 1 (PD-L1).
SHANGHAI – On June 1 of this year, China's new Cybersecurity Law came into effect, tightening the government's grip on the transfer and security of data collected in China. Now that the law is in place, industry regulators are expected to hammer out specific rules that will come out in 2018. There are signs that drugmakers, and those collecting clinical trial data, could face some tough constraints making it difficult for patient data to leave the country.
SHANGHAI – On June 1 of this year, China’s new Cybersecurity Law came into effect, tightening the government’s grip on the transfer and security of data collected in China. Now that the law is in place, industry regulators are expected to hammer out specific rules that will come out in 2018.
SUZHOU, China – "It is not enough to try to understand the molecular system behind the disease. You have to understand the importance of each partner in that pathway and pick the right pathway."
SUZHOU, China – At the 3rd DIA China Drug Discovery Innovation, a director from the Ministry of Science and Technology (MOST) outlined the government's proposed plans to accelerate approvals for the collection of human genetic resources in keeping with the central government's overall strategy to support innovative drug development.
SUZHOU, China – At the 3rd DIA China Drug Discovery Innovation this week a director from the Ministry of Science and Technology (MOST) outlined the government's proposed plans to accelerate approvals for the collection of human genetic resources in keeping with the central government's overall strategy to support innovative drug development.
